R-verapamil - AGI Therapeutics
Alternative Names: AGI-003; Arverapamil - AGI Therapeutics; RezularLatest Information Update: 30 Sep 2009
At a glance
- Originator AGI Therapeutics
- Class Analgesics; Antiarrhythmics; Antihyperglycaemics; Antihypertensives; Antineoplastics; Irritable bowel syndrome therapies; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules
- Mechanism of Action Calcium channel antagonists; Melatonin receptor modulators; Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Irritable bowel syndrome
Most Recent Events
- 22 Sep 2009 Final adverse events data from a Phase-III trial, ARDIS-1, in Diarrhoea-predominant irritable bowel syndrome released by AGI Therapeutics
- 15 May 2009 Discontinued - Phase-III for Irritable bowel syndrome in European Union (PO)
- 15 May 2009 Discontinued - Phase-III for Irritable bowel syndrome in South America (PO)